• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis.

作者信息

Lu Jia-Wei, Zhang Mei-Hua, Gopee Shehzad, Lu Yan

机构信息

Department of Dermatology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

出版信息

J Dermatol. 2021 Oct;48(10):E494-E495. doi: 10.1111/1346-8138.16041. Epub 2021 Jul 13.

DOI:10.1111/1346-8138.16041
PMID:34254698
Abstract
摘要

相似文献

1
Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis.一名斑块状银屑病患者应用司库奇尤单抗后出现皮肤结节病。
J Dermatol. 2021 Oct;48(10):E494-E495. doi: 10.1111/1346-8138.16041. Epub 2021 Jul 13.
2
Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis.司库奇尤单抗诱发斑块状银屑病患者出现瘢痕结节病。
Australas J Dermatol. 2022 May;63(2):e187-e189. doi: 10.1111/ajd.13799. Epub 2022 Feb 9.
3
Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.阿达木单抗治疗慢性斑块状银屑病过程中并发结节病。
Australas J Dermatol. 2011 Aug;52(3):e8-11. doi: 10.1111/j.1440-0960.2010.00660.x. Epub 2010 Jun 23.
4
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.司库奇尤单抗治疗指甲银屑病的临床疗效和疾病负担的影响：随机安慰剂对照 TRANSFIGURE 试验的 32 周结果。
Br J Dermatol. 2019 Nov;181(5):954-966. doi: 10.1111/bjd.17351. Epub 2019 Jan 16.
5
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病148周的疗效和安全性：2PRECISE研究的扩展
J Am Acad Dermatol. 2021 Feb;84(2):552-554. doi: 10.1016/j.jaad.2020.06.038. Epub 2020 Jun 18.
6
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.司库奇尤单抗在治疗中度至重度银屑病患者中，通过两年治疗展现出持续清除皮肤症状及改善患者报告结局的疗效：CLEAR研究结果
J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6.
7
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
8
Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index.八名患者在银屑病面积和严重程度指数达到0分后停用司库奇尤单抗的临床病程及背景
J Dermatol. 2021 Aug;48(8):e380-e381. doi: 10.1111/1346-8138.15948. Epub 2021 May 18.
9
Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis.接受司库奇尤单抗治疗的银屑病患者出现罕见复发：线状银屑病。
Dermatol Ther. 2020 May;33(3):e13346. doi: 10.1111/dth.13346. Epub 2020 May 3.
10
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.司库奇尤单抗：中重度儿童斑块状银屑病治疗药物。
Paediatr Drugs. 2021 Nov;23(6):601-608. doi: 10.1007/s40272-021-00476-w. Epub 2021 Oct 19.

引用本文的文献

1
IL17 in Sarcoidosis - A level playing field?结节病中的白细胞介素17——公平竞争环境？
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Jun 25;42(2):16288. doi: 10.36141/svdld.v42i2.16288.
2
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.白细胞介素-17A抑制剂司库奇尤单抗的安全性综述
Pharmaceuticals (Basel). 2022 Nov 7;15(11):1365. doi: 10.3390/ph15111365.